UNC2881Mer tyrosine kinase inhibitor CAS# 1493764-08-1 |
- TCS 359
Catalog No.:BCC1183
CAS No.:301305-73-7
- Cabozantinib (XL184, BMS-907351)
Catalog No.:BCC1264
CAS No.:849217-68-1
- Amuvatinib (MP-470, HPK 56)
Catalog No.:BCC2258
CAS No.:850879-09-3
- TG101209
Catalog No.:BCC2198
CAS No.:936091-14-4
- Ponatinib (AP24534)
Catalog No.:BCC2522
CAS No.:943319-70-8
- Quizartinib (AC220)
Catalog No.:BCC2548
CAS No.:950769-58-1
Quality Control & MSDS
Chemical structure
3D structure
Number of papers citing our products
| Cas No. | 1493764-08-1 | SDF | Download SDF |
| PubChem ID | 71721525 | Appearance | Powder |
| Formula | C25H33N7O2 | M.Wt | 463.58 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 44 mg/mL (94.91 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-(butylamino)-4-[(4-hydroxycyclohexyl)amino]-N-[(4-imidazol-1-ylphenyl)methyl]pyrimidine-5-carboxamide | ||
| SMILES | CCCCNC1=NC=C(C(=N1)NC2CCC(CC2)O)C(=O)NCC3=CC=C(C=C3)N4C=CN=C4 | ||
| Standard InChIKey | NPVXOWLPOFYACO-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C25H33N7O2/c1-2-3-12-27-25-29-16-22(23(31-25)30-19-6-10-21(33)11-7-19)24(34)28-15-18-4-8-20(9-5-18)32-14-13-26-17-32/h4-5,8-9,13-14,16-17,19,21,33H,2-3,6-7,10-12,15H2,1H3,(H,28,34)(H2,27,29,30,31) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | UNC2881 is a specific inhibitor of Mer tyrosine kinase with IC50 value of 4.3 nM. | |||||
| Targets | Mer tyrosine kinase | |||||
| IC50 | 4.3 nM | |||||
UNC2881 Dilution Calculator
UNC2881 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1571 mL | 10.7856 mL | 21.5712 mL | 43.1425 mL | 53.9281 mL |
| 5 mM | 0.4314 mL | 2.1571 mL | 4.3142 mL | 8.6285 mL | 10.7856 mL |
| 10 mM | 0.2157 mL | 1.0786 mL | 2.1571 mL | 4.3142 mL | 5.3928 mL |
| 50 mM | 0.0431 mL | 0.2157 mL | 0.4314 mL | 0.8628 mL | 1.0786 mL |
| 100 mM | 0.0216 mL | 0.1079 mL | 0.2157 mL | 0.4314 mL | 0.5393 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
UNC2881 is a selective inhibitor of Mer tyrosine kinase [1].
Mer is a member of the TAM (Tyro3, Axl and Mer) receptor tyrosine kinase (RTK) subfamily with growth-arrest-specific-6 (Gas6) as an endogenous ligand. Mer plays an important role in platelet aggregation and macrophage activity.
UNC2881 is a novel and specific Mer tyrosine kinase inhibitor. In kinase inhibition assays, UNC2881 (430 nM) inhibited MER, FGFR1, KDR, EGFR, ITK and TRKA by greater than 50%. In 697 B-ALL cells, UNC2881 inhibited Mer phosphorylation with IC50 value of 22 nM. Also, UNC2881 inhibited ligand-dependent phosphorylation of a chimeric protein consisting of the intracellular domain of Mer and the extracellular domain of the epidermal growth factor receptor (EGFR). In human platelet-rich plasma, UNC2881 inhibited platelet aggregation induced by fibrillar Type I equine collagen by greater than 25%. UNC2881 also inhibited ATP release, a marker of platelet activation [1].
In mice, UNC2881 exhibited 14% oral bioavailability and high systemic clearance. UNC2881 was sufficient for in vitro or short-term in vivo studies [1].
Reference:
[1]. Zhang W, McIver AL, Stashko MA, et al. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. J Med Chem, 2013, 56(23): 9693-9700.
- 1,2,3,4,6-O-Pentagalloylglucose
Catalog No.:BCN2338
CAS No.:14937-32-7
- UNC2250
Catalog No.:BCC4876
CAS No.:1493694-70-4
- AACOCF3
Catalog No.:BCC7075
CAS No.:149301-79-1
- Cytochalasin B
Catalog No.:BCN7084
CAS No.:14930-96-2
- pp60 c-src (521-533) (phosphorylated)
Catalog No.:BCC5851
CAS No.:149299-77-4
- 1-Dehydroxy-23-deoxojessic acid
Catalog No.:BCN1663
CAS No.:149252-87-9
- De-4'-O-methylyangambin
Catalog No.:BCN1662
CAS No.:149250-48-6
- Neotripterifordin
Catalog No.:BCN7477
CAS No.:149249-32-1
- Arcaine sulfate
Catalog No.:BCC6631
CAS No.:14923-17-2
- Z-Ser(Tos)-OMe
Catalog No.:BCC2741
CAS No.:1492-52-0
- H-Abu-OH
Catalog No.:BCC3198
CAS No.:1492-24-6
- Benserazide HCl
Catalog No.:BCC4468
CAS No.:14919-77-8
- Cidofovir dihydrate
Catalog No.:BCC4247
CAS No.:149394-66-1
- NE 100 hydrochloride
Catalog No.:BCC7573
CAS No.:149409-57-4
- Poncirin
Catalog No.:BCN2590
CAS No.:14941-08-3
- Traxillaside
Catalog No.:BCN6917
CAS No.:149415-62-3
- Hypocrellin C
Catalog No.:BCN3398
CAS No.:149457-83-0
- Ganoderic acid AM1
Catalog No.:BCN2441
CAS No.:149507-55-1
- Marmin
Catalog No.:BCN1665
CAS No.:14957-38-1
- Stachybotramide
Catalog No.:BCN6969
CAS No.:149598-71-0
- Impentamine dihydrobromide
Catalog No.:BCC7197
CAS No.:149629-70-9
- MOG (35-55)
Catalog No.:BCC3670
CAS No.:149635-73-4
- Vorinostat (SAHA, MK0683)
Catalog No.:BCC2145
CAS No.:149647-78-9
- Nafadotride
Catalog No.:BCC7025
CAS No.:149649-22-9
Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.[Pubmed:24219778]
J Med Chem. 2013 Dec 12;56(23):9693-700.
The role of Mer kinase in regulating the second phase of platelet activation generates an opportunity to use Mer inhibitors for preventing thrombosis with diminished likelihood for bleeding as compared to current therapies. Toward this end, we have discovered a novel, Mer kinase specific substituted-pyrimidine scaffold using a structure-based drug design and a pseudo ring replacement strategy. The cocrystal structure of Mer with two compounds (7 and 22) possessing distinct activity have been determined. Subsequent SAR studies identified compound 23 (UNC2881) as a lead compound for in vivo evaluation. When applied to live cells, 23 inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM. Treatment with 23 is also sufficient to block EGF-mediated stimulation of a chimeric receptor containing the intracellular domain of Mer fused to the extracellular domain of EGFR. In addition, 23 potently inhibits collagen-induced platelet aggregation, suggesting that this class of inhibitors may have utility for prevention and/or treatment of pathologic thrombosis.
